USFDA Turns Its Gaze On Ranbaxy
  • Prabha Hedge
  • Jan 13 2014

January 13: Ranbaxy today said that it has received Form 483 from the U.S. FDA with some observations for its Toansa API plant. Analysts say that if the company is not able to address the concerns of U.S. FDA then an import alert could be issued which would have a significant impact on the company's financials. Bloomberg TV India’s Priya Sheth shares a detailed report on the same.